Lexeo Therapeutics, Inc.
LXEO · XNASCIK 1907108fmd_18ECD76B9SVCAX1P71QRD39S7DManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2022 to Jun 30, 2026, 18 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total revenues | 1 | – | – | – |
| Research and development | 49 | 53 | 74 | 64 |
| Total operating expenses | 61 | 69 | 106 | 109 |
| Operating income | (61) | (69) | (106) | (109) |
| Interest expense | 0 | 0 | 0 | 0 |
| Interest and investment income | 1 | 3 | 8 | 6 |
| Other non-operating income (expense) | 1 | 2 | 7 | 9 |
| Income before taxes | (59) | (66) | (98) | (100) |
| Income tax expense | – | – | 0 | 0 |
| Net income from continuing operations | – | – | (98) | (100) |
| Net income | (59) | (66) | (98) | (100) |